Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

Summary

Participation Requirements

Description

This is a single arm, window of opportunity study in which participants with previously untreated triple negative breast cancers (TNBC) who are candidates for potentially curative surgery will receive one 21-day cycle of therapy prior to surgery, consisting of lenvatinib 12 mg daily, days 1 through ...

This is a single arm, window of opportunity study in which participants with previously untreated triple negative breast cancers (TNBC) who are candidates for potentially curative surgery will receive one 21-day cycle of therapy prior to surgery, consisting of lenvatinib 12 mg daily, days 1 through 14, and pembrolizumab 200 mg IV on day 1. Participants will undergo surgical resection of the primary breast tumor 7-10 days after the last dose of lenvatinib. Post-operative adjuvant therapies will be at the discretion of the treating oncologist. Post-Surgery Follow-Up information will be collected at assessments at 3 months post-op and after that every 6 months until 5 years after surgery

Tracking Information